Equities Analysts Offer Predictions for CORT FY2026 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research raised their FY2026 earnings per share estimates for Corcept Therapeutics in a note issued to investors on Wednesday, August 19th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $1.02 for the year, up from their prior estimate of $0.38. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.62 EPS, Q1 2027 earnings at $0.11 EPS, Q2 2027 earnings at $0.51 EPS, FY2027 earnings at $1.91 EPS, Q1 2028 earnings at $0.41 EPS, Q2 2028 earnings at $1.17 EPS and FY2028 earnings at $4.07 EPS.

Other analysts have also issued research reports about the company. Truist Financial assumed coverage on Corcept Therapeutics in a research note on Tuesday. They set a “buy” rating and a $164.00 price objective for the company. Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. HC Wainwright increased their price target on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Finally, Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a report on Monday, July 27th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $138.17.

Corcept Therapeutics Price Performance

CORT opened at $121.05 on Friday. The stock’s 50 day simple moving average is $96.60 and its 200 day simple moving average is $64.19. The firm has a market cap of $13.09 billion, a price-to-earnings ratio of 288.22 and a beta of 0.45. Corcept Therapeutics has a 1 year low of $28.66 and a 1 year high of $122.21.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. The company had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.Corcept Therapeutics’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics during the third quarter valued at approximately $25,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Corcept Therapeutics in the second quarter worth $27,000. Larson Financial Group LLC raised its holdings in Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 442 shares in the last quarter. Gould Capital LLC lifted its position in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 200 shares during the period. Finally, Torren Management LLC purchased a new position in Corcept Therapeutics during the fourth quarter valued at $25,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Activity

In related news, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $111.43, for a total transaction of $1,114,300.00. Following the transaction, the director owned 1,074,543 shares in the company, valued at $119,736,326.49. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sean Maduck sold 3,664 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $114.49, for a total transaction of $419,491.36. Following the completion of the transaction, the insider directly owned 9,755 shares of the company’s stock, valued at approximately $1,116,849.95. The trade was a 27.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 520,146 shares of company stock worth $48,903,764. 20.70% of the stock is owned by company insiders.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Broad earnings-estimate increases: Zacks Research raised its EPS forecasts across multiple periods, including FY2026 to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also lifted, including Q1 2027 from a $0.17 loss to $0.11 earnings and Q2 2028 to $1.17 from $0.69. The revisions signal improving expectations for Corcept’s growth and profitability, though Zacks maintained a “Hold” rating.
• Positive Sentiment: Bullish growth thesis and analyst targets: An investment analysis rated CORT a “Strong Buy,” citing the launch of Lifyorli for platinum-resistant ovarian cancer, continued Korlym growth, projected revenue growth above 44%, and significant margin expansion. The analysis set one- and two-year price targets of $163 and $222, respectively. Recent Wall Street targets have also clustered well above the current trading level, including $164 from Truist and $165 from Piper Sandler and HC Wainwright. Corcept Therapeutics growth analysis
• Positive Sentiment: Strong recent operating results: Corcept’s latest quarterly report showed EPS of $0.36 versus the $0.02 consensus estimate and revenue of $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, reinforcing the case for upward estimate revisions.
• Neutral Sentiment: Valuation is demanding: Corcept has a market capitalization of approximately $13.1 billion and a reported price-to-earnings ratio above 288, leaving the stock sensitive to any slowdown in growth or disappointment in its pipeline.
• Negative Sentiment: Director sold a substantial stake: Director David Mahoney sold 103,606 shares for approximately $12.25 million, reducing his holdings by 8.37%. He still owns more than 1.13 million shares, but the transaction may weigh modestly on sentiment because it represents sizable insider selling. Corcept Therapeutics insider sale

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.